This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

39/100

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

A total of 143 patients with cognitive concerns were included who underwent a PrecivityAD2 test as part of their clinical evaluation. The average patient age was 74.5 ± 6.6 years (mean ± standard deviation), 48% were female, 94% were White, and 76% were positive by PrecivityAD2. A sub-cohort of 34 patients were treated with the anti-amyloid antibody lecanemab. The median APS2 value in the treated sub-cohort was 97, with 75% of patients having an APS2 of 87 or higher. Twenty-one patients additionally underwent either amyloid PET or CSF testing (Figure 1). PrecivityAD2 agreed with CSF tests in all fourteen patients with both tests (nine positive and 5 negative). PrecivityAD2 agreed with amyloid PET in six PET positive patients. PrecivityAD2 was negative in one PET positive patient, but the PET report noted, "Suboptimal study due to low signal-to-noise ratio," suggesting the PET read may be false positive. If CSF or PET is considered the reference standard, PrecivityAD2 had a positive predictive value of 100% and negative predictive value of 83%. In 21 patients who underwent a second test with CSF or PET, all 15 patients who were positive by PrecivityAD2 were also positive by CSF or PET. Although this study is very small, these data support providing anti-amyloid treatments based on high accuracy blood biomarker tests to patients with a high clinical likelihood of amyloid pathology.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Schindler, S. E., Hofmann, A., Paczynski, M., Posey, Z. J., Aldinger, M., Benzinger, T. L., et al. (2025). Determining eligibility for anti‐amyloid treatments using blood biomarkers. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_097511

Vancouver

Schindler SE, Hofmann A, Paczynski M, Posey ZJ, Aldinger M, Benzinger TL, et al. Determining eligibility for anti‐amyloid treatments using blood biomarkers. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_097511. PMID: 41442134.

BibTeX

@article{schindler2025-41442134,
  author  = {Schindler, Suzanne Elizabeth and Hofmann, Anna and Paczynski, Madeline and Posey, Zachary J and Aldinger, Melissa and Benzinger, Tammie L.S. and Morris, John C. and Snider, Barbara Joy},
  title   = {{Determining eligibility for anti‐amyloid treatments using blood biomarkers}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_097511},
  pmid    = {41442134},
  url     = {https://doi.org/10.1002/alz70856_097511}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

A total of 143 patients with cognitive concerns were included who underwent a PrecivityAD2 test as part of their clinical evaluation.
The average patient age was 74.5 ± 6.6 years (mean ± standard deviation), 48% were female, 94% were White, and 76% were positive by PrecivityAD2.
A sub-cohort of 34 patients were treated with the anti-amyloid antibody lecanemab.
The median APS2 value in the treated sub-cohort was 97, with 75% of patients having an APS2 of 87 or higher.
Twenty-one patients additionally underwent either amyloid PET or CSF testing (Figure 1).

Why it matters

In a very small group of 143 patients, the PrecivityAD2 blood test agreed with CSF or PET results in those who had both tests, and 34 patients were treated with lecanemab. The authors state the study is very small but support using high-accuracy blood biomarker tests to guide anti-amyloid treatment in patients with high clinical likelihood of amyloid pathology.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants4,000
Evidence strengthModerate

How this study scored 39/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	3 / 4	4,000 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 3 year(s) since 2025
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	1 / 4	Last-listed author Barbara Joy Snider: h-index 5 (OpenAlex, whole career)
Institution's track record	2 / 3	Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multi-centre collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41442134)
Free to read	2 / 2	Free to read
Total	39 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Related studies in Biomarkers

Also in Biomarkers

204 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.

Similar studies

More on Biomarkers

See all studies in Biomarkers →